𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

✍ Scribed by Bauer, S; Hilger, R A; Mühlenberg, T; Grabellus, F; Nagarajah, J; Hoiczyk, M; Reichardt, A; Ahrens, M; Reichardt, P; Grunewald, S; Scheulen, M E; Pustowka, A; Bock, E; Schuler, M; Pink, D

Book ID
126811924
Publisher
Nature Publishing Group
Year
2014
Tongue
English
Weight
506 KB
Volume
110
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Resection of residual disease in patient
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib
✍ Sebastian Bauer; Jörg Thomas Hartmann; Maike de Wit; Hauke Lang; Florian Grabell 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 723 KB

## Abstract Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Long‐term survival of patients with metastatic disease has only been observed in patients with completely resected disease. Recently, the tyrosine kinase inhibitor imatinib has b